Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27529821 | 0.86 | CNR1 (0.39) | KMT2AALDH1A1APLNRCNR1PDCD1 | |
| SCHEMBL16929988 | 0.84 | CA2 (0.50) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL7095189 | 0.83 | KDM4E (0.51) | KMT2AKDM4EGLAGAAMAPT | |
| SCHEMBL8838326 | 0.82 | KDM4E (0.49) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL26093135 | 0.82 | ALDH1A1 (0.53) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL10801524 | 0.79 | BCL9 (0.48) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL7755696 | 0.78 | KMT2A (0.48) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL7656402 | 0.78 | ALOX15 (0.48) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL298382 | 0.77 | AR (0.50) | KMT2AALDH1A1KDM4EGLAGAA | |
| SCHEMBL238087 | 0.77 | APLNR (0.63) | KMT2AALDH1A1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610268-A1 | CELL-MEMBRANE-PERMEABLE PEPTIDE FOR CONJUGATION | AGC INC. (JP) | 2025-09-03 | — | — | EP | disclosed |
| CN-119431135-B | Preparation method of 4- (4-hydroxymethyl-3-methoxyphenoxy) butyric acid | 安徽昊帆生物有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119431135-A | Preparation method of 4- (4-hydroxymethyl-3-methoxyphenoxy) butyric acid | 安徽昊帆生物有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3995486-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC INC. (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | AGC Inc. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10358470-B2 | Glycosylated polypeptide and pharmaceutical composition containing same | GLYTECH, INC. (JP) | 2019-07-23 | — | — | US | disclosed |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180296686-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE US DEPARTMENT OF HEALTH &HUMAN SERVICES (US) | 2018-10-18 | — | — | US | disclosed |
| US-20030125516-A1 | Methods and compositions for peptide synthesis | TRIMERIS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6469136-B1 | SOLID PHASE/LIQUID PHASE SYNTHESIS; PURIFICATION; AMINO ACID SEQUENCES | TRIMERIS, INC. | 2002-10-22 | — | — | US | disclosed |
| WO-2001034635-A9 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS INC (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1071442-A4 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS INC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6281331-B1 | A SET OF T-20 PEPTIDE FRAGMENTS SYNTHESIZED BY SOLID AND LIQUID PHASE SYNTHESIS; FOR LARGE SCALE PRODUCTION FOR USE IN THERAPEUTICS OF HUMAN IMMUNODEFICIENCY VIRUS-1 | TRIMERIS, INC. | 2001-08-28 | — | — | US | disclosed |
| CN-1303299-A | Method and compositions for peptide synthesis | TRIMERIS INC (US) | 2001-07-11 | — | — | CN | disclosed |
| WO-2001034635-A2 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1071442-A1 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS INC. (US) | 2001-01-31 | — | — | EP | disclosed |
| US-6015881-A | COUPLING TOGETHER SPECIFIC SIDE-CHAIN PROTECTED PEPTIDE FRAGMENTS, DEPROTECTING AMINO TERMINUS, REACTING WITH ANOTHER PROTECTED PEPTIDE, MODIFYING AMINO TERMINUS TO ACETYL GROUP, DEPROTECTING SIDE-CHAINS; HIGH PURITY; GREATER LOAD | TRIMERIS, INC. | 2000-01-18 | — | — | US | disclosed |
| WO-1999048513-A1 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358470-B2 | Glycosylated polypeptide and pharmaceutical composition containing same | IFNG, IFNAR1, IAPP | KMT2A 4694/4885ALDH1A1 3871/4885KDM4E 4841/4885 |
| US-10905769-B2 | Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use | PLK1, POLR1E, POLK | KMT2A 1885/4885ALDH1A1 4834/4885KDM4E 2771/4885 |
| US-20180296686-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, POLR1E, POLK | KMT2A 1885/4885ALDH1A1 4834/4885KDM4E 2771/4885 |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | MMP2, DNASE1L3, DNASE1 | KMT2A 4101/4885ALDH1A1 620/4885KDM4E 3654/4885 |
| US-20220119440-A1 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | VIP, RFC2, QRFPR | KMT2A 2571/4885ALDH1A1 4069/4885KDM4E 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.